Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APPROACH: Macitentan (Opsumit) vs Maciten in pulmonary arterial hypertension
KCT0009551Phase 4Recruiting
- Sponsor
- Samjin Pharmaceutical Co., Ltd.
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of macitentan in pulmonary arterial hypertension (PAH) (2 arms), sponsored by Samjin Pharmaceutical Co., Ltd. Started Oct 2024; status: recruiting.
02
Drugs
macitentan
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on KCT0009551.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0009551.